Compare CCCC & WNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCCC | WNC |
|---|---|---|
| Founded | 2015 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Construction/Ag Equipment/Trucks |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 404.7M | 325.8M |
| IPO Year | 2020 | 2009 |
| Metric | CCCC | WNC |
|---|---|---|
| Price | $3.73 | $12.93 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 1 |
| Target Price | ★ $12.20 | $11.00 |
| AVG Volume (30 Days) | ★ 2.6M | 1.5M |
| Earning Date | 05-06-2026 | 05-01-2026 |
| Dividend Yield | N/A | ★ 3.84% |
| EPS Growth | 16.45 | ★ 179.22 |
| EPS | ★ N/A | N/A |
| Revenue | $35,947,000.00 | ★ $2,027,489,000.00 |
| Revenue This Year | N/A | $10.65 |
| Revenue Next Year | N/A | $14.06 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 1.02 | ★ 8.81 |
| 52 Week Low | $1.69 | $6.63 |
| 52 Week High | $5.17 | $14.32 |
| Indicator | CCCC | WNC |
|---|---|---|
| Relative Strength Index (RSI) | 47.01 | 50.42 |
| Support Level | $3.42 | $11.63 |
| Resistance Level | $3.91 | $12.94 |
| Average True Range (ATR) | 0.22 | 0.72 |
| MACD | 0.00 | -0.20 |
| Stochastic Oscillator | 47.46 | 35.87 |
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
Wabash National Corp operates as the innovation leader of connected solutions for the transportation, logistics, and distribution industries. The Company manages its business in two operating and reportable segments: Transportation Solutions and Parts & Services. It designs and manufactures products including dry freight and refrigerated trailers, platform trailers, tank trailers, dry and refrigerated truck bodies, structural composite panels and products, trailer aerodynamic solutions, and specialty food-grade processing equipment.